Table 2.
Results of the systematic reviews of new drugs as add-on therapy in partial-onset epilepsy [McCorry et al. 2004].
| AED | Number of trials | Daily dose range (mg/day) | Effect estimate (95% CI) for a 50% reduction in seizures compared with placebo∗ | Relative risk (95% CI) of treatment withdrawal compared with placebo∗ |
| Gabapentin | 5 | 600-1800 | OR 1.93 (1.37-2.7) | 1.05 (0.68-1.61) |
| Tiagabine | 3 | 16-56 | RR 3.16 (1.97-5.07) | 1.80 (1.2-2.7) |
| Topiramate | 9 | 200-1000 | RR 3.32 [2.52-4.39] | 2.06 (1.38-3.08) |
| Lamotrigine | 11 | 200-500 | OR 2.71 (1.87-3.61) | 1.10 (0.81-1.50) |
| Levetiracetam | 4 | 1000-3000 | OR 3.78 (2.62-5.44) | 1.21 (0.88-1.66) |
| Oxcarbazepine | 2 | 600-2400 | OR 2.51 (1.88-3.33) | 1.72 (1.35-2.18) |
| Zonisamide | 3 | 400 | OR 2.46 (1.61-3.74) | 1.46 (1.02-2.62) |
∗
All results are calculated for all doses. Note that 95% CIs that include 1 indicate no statistically significant difference. OR, odds ratio; RR, risk ratio.